As­traZeneca castoff draws $123M wa­ger on CX­CR2 an­tag­o­nist as Are­na lines up a buy­out op­tion

Back in 2018, James Mack­ay — then lead­ing an in­flam­ma­to­ry dis­ease group at As­traZeneca af­ter lead­ing the phar­ma gi­ant’s ac­qui­si­tion of Ardea — took in­ter­est in a drug that’d been rel­e­gat­ed to the shelves four years ear­li­er.

Where As­traZeneca once saw a dis­ap­point­ing COPD drug, he saw a Phase II-ready can­di­date that could tack­le a slate of se­ri­ous con­di­tions.

So he grabbed AZD4721, re­named it RIST4721, spun out a new com­pa­ny named Aris­tea Ther­a­peu­tics, re­cruit­ed a bench of ex­pe­ri­enced drug de­vel­op­ers and got $15 mil­lion from No­vo Hold­ings.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER